

Conflict of interest

The authors declare no conflict of interest.

References

1. Von Eyben FE, Kairemo K. Meta-analysis of (11)C-choline and (18)F-choline PET/CT for management of patients with prostate cancer. *Nucl Med Commun.* 2014 Mar;35(3):221–230.
2. Pomper MG, Mease RC, Foss CA. PET imaging in prostate cancer: focus on prostate-specific membrane antigen. *Curr Top Med Chem.* 2013;13(8):951–962. Review.
3. Niibe Y, Chang JY. Novel insights of oligometastases and oligo-recurrence and review of the literature. *Pulm Med.* 2012;2012:261096.
4. Schick U, Jorcano S, Nouet P, et al. Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases. *Acta Oncol.* 2013;52:1622–1628.
5. Decaestecker K, De Meerleer G, Ameye F, et al. Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial. *BMC Cancer.* 2014;14:671.